Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The nigrostriatal dopaminergic system (NDS) controls motor activity, and its impairment during type 2 diabetes (T2D) progression could increase Parkinson's disease risk in diabetics. If so, whether glycemia regulation prevents this impairment needs to be addressed. We investigated whether T2D impairs the NDS and whether dipeptidyl peptidase-4 inhibition (DPP-4i; a clinical strategy against T2D but also neuroprotective in animal models) prevents this effect, in middle-aged mice. Neither T2D (induced by 12 months of high-fat diet) nor aging (14 months) changed striatal dopamine content assessed by high-performance liquid chromatography. However, T2D reduced basal and amphetamine-stimulated striatal extracellular dopamine, assessed by microdialysis. Both the DPP-4i linagliptin and the sulfonylurea glimepiride (an antidiabetic comparator unrelated to DPP-4i) counteracted these effects. The functional T2D-induced effects did not correlate with NDS neuronal/glial alterations. However, aging itself affected striatal neurons/glia, and the glia effects were counteracted mainly by DPP-4i. These findings show NDS functional pathophysiology in T2D and suggest the preventive use of two unrelated anti-T2D drugs. Moreover, DPP-4i counteracted striatal age-related glial alterations suggesting striatal rejuvenation properties.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.neurobiolaging.2020.01.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exploring DPP-4: Implications in diverse diseases and structural insights for novel inhibitor design.
Bioorg Chem
September 2025
Department of Pharmaceutical Technology, JIS University, 81, Nilgunj Road, Agarpara, Kolkata 700109, West Bengal, India; Department of Pharmacy, University of Salerno, Via Giovanni Paolo II, 132, 84084 Fisciano, SA, Italy. Electronic address:
Dipeptidyl peptidase-4 (DPP-4) is a multifaceted enzyme that orchestrates a variety of physiological and pathological processes, making it a pivotal target in the treatment of several diseases. Notably, the role of DPP-4 extends beyond its well-documented involvement in glucose metabolism and type 2 diabetes mellitus (T2DM) management, where DPP-4 inhibitors (gliptins) have gained prominence. Emerging evidence highlights its significant functions in immune regulation, cardiovascular diseases, cancer, and inflammatory disorders.
View Article and Find Full Text PDFObesity hinders the efficacy of adipose-derived stem cells for knee osteoarthritis by reducing the proportion of DPP4+ stem cells.
Stem Cells Transl Med
July 2025
Department of Joint Surgery and Translational Medical Center for Stem Cell Therapy, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, People's Republic of China.
Osteoarthritis (OA) is the most prevalent and disabling joint disease, while adipose-derived stem cells (ASCs) have emerged as a promising therapeutic option in pre-clinical studies. However, the therapeutic efficacy of ASCs may be influenced by the source of these cells, especially in obese patients. This study compared the effects of intra-articular injections of ASCs from wild-type (WT) and ob/ob (OB) mice.
View Article and Find Full Text PDFhas long been used in folk medicine to treat a variety of ailments, including diabetes, skin disorders, dropsy, cuts, wounds, ulcers, fever, and blood disorders, etc., which are generally categorized under the complications of diabetes mellitus. Various species of this genus have also been verified to possess strong anti-diabetic activity.
View Article and Find Full Text PDFThe Causal Mechanism Between the Dipeptidyl Peptidase-4, Heart Failure, and Other Cardiovascular Diseases: A Mendelian Randomization and Mediation Study.
Int J Endocrinol
August 2025
School of Medicine, Chang Gung University, Taoyuan, Taiwan.
Dipeptidyl peptidase-4 (DPP4) inhibitors are commonly used to treat type 2 diabetes. However, the causality of it on cardiovascular diseases (CVDs) is controversial. This study aimed (1) to investigate the causal mechanisms of DPP4 gene expression at the mRNA level on CVDs, including all-cause heart failure (HF), atrial fibrillation (AF), myocardial infarction (MI), and stroke in a European population; (2) to assess the direct effect of DPP4 at the mRNA level on CVD, which is independent of type-2 diabetes; and (3) to explore the causality of DPP4 inhibition on CVDs and type-2 diabetes.
View Article and Find Full Text PDFWeight loss interventions and obesity-associated cancers in people with type 2 diabetes and overweight/obesity: A real-world observational study.
Diabetes Obes Metab
September 2025
NIHR Leicester Biomedical Research Centre, University Hospitals of Leicester NHS Trust, Leicester, UK.
Aims: To evaluate whether weight-loss interventions are associated with obesity-associated cancers (OAC) in individuals with overweight/obesity and type 2 diabetes (T2D).
Materials And Methods: This retrospective cohort study utilised the TriNetX federated research network. Three cohorts of adults with overweight/obesity and T2D, treated with either semaglutide, tirzepatide or bariatric surgery (BS) between June 2005 and June 2025, were propensity score matched (1:1) to cohorts treated with dipeptidyl peptidase-4 inhibitors (DPP-4i) using potential confounding factors.